OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
What to know about lung adenocarcinoma following Pope Leo diagnosis
October 14, 2026
The University of Cincinnati Cancer Center's Robert Van Haren, MD, was featured in a Medical News Today article discussing the diagnosis, risk factors, symptoms and treatment of lung adenocarcinoma in light of Pope Leo XIV's recent diagnosis.
UC researchers help demonstrate proof-of-concept gene therapy for hydrocephalus
October 14, 2026
A proof-of-concept study led by UC’s Agnes (Yu) Luo, PhD, and collaborators at UC Davis shows that an adeno-associated virus (AAV) gene therapy can reduce hydrocephalus-associated tissue damage in animal models, pointing to a potential new treatment strategy.
How Ohio's political landscape has changed
October 13, 2026
UC Professor David Niven tells Spectrum News that Ohio has become a Republican stronghold after once serving as a bellwether for national elections.